2026-08-25T15:29:58-05:00 2025-12-31 331374517 PKF O'CONNOR DAVIES ADVISORY LLC 3001 SUMMER STREET 5TH FLOOR EAST STAMFORD CT 06905 990 2025-01-01 061504413 THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC MULT 2032290464 383 MAIN AVENUE 7TH FL NORWALK CT 06851 MICHAEL ANDREINI PRESIDENT & CEO 2032290464 2026-08-25 1 MELISSA MODELSON P01603524 2033232400 2026-08-25 2025 2025-03-06 01:10:19Z MICHAEL ANDREINI 383 MAIN AVENUE 7TH FL NORWALK CT 06851 120070404 0 X WWW.THEMMRF.ORG X 1998 CT SEE SCHEDULE O 14 14 80 200 0 0 24100727 26628081 2261716 8674361 2238351 1150050 500620 70864 29101414 36523356 6080876 3576906 0 0 11390435 12331616 0 0 6107004 18133026 18742609 35604337 34651131 -6502923 1872225 66397148 62872951 16374755 14844396 50022393 48028555 X SEE SCHEDULE O 0 0 6096220 0 8674361 THE MULTIPLE MYELOMA RESEARCH CONSORTIUM (MMRC), THE CLINICAL RESEARCH SUBSIDIARY OF THE MULTIPLE MYELOMA RESEARCH FOUNDATION (MMRF), IS A COLLABORATIVE NETWORK OF LEADING CANCER CENTERS DRIVING CUTTING-EDGE CLINICAL TRIALS. THE MMRF LAUNCHED THE HORIZON CLINICAL TRIALS PROGRAM THROUGH THE MMRC TO DRIVE PROGRESS FOR PATIENTS WHO NEED IT MOST. HORIZON TRIALS USE AN ADAPTIVE PLATFORM DESIGN THAT ALLOWS RESEARCHERS TO TEST SEVERAL TREATMENTS AT THE SAME TIME AND ADD NEW OPTIONS AS DATA BECOMES AVAILABLE. IN 2025, THE HORIZON ONE TRIAL FOCUSED ON RELAPSED/REFRACTORY MYELOMA EXCEEDED MANY OF ITS ENROLLMENT GOALS FOR ITS FIRST TREATMENT ARM, WHICH IS TESTING DOSING APPROACHES FOR A BISPECIFIC ANTIBODY. THE TRIAL SO FAR HAS ENROLLED MORE BLACK PATIENTS AND OLDER ADULTSTWO GROUPS THAT HAVE HISTORICALLY BEEN LEFT OUT OF RESEARCHTHAN MOST MYELOMA TRIALS. HORIZON ONE BECAME THE FIRST-EVER MYELOMA CLINICAL TRIAL IN FLINT, MICHIGAN, AND IT OPENED AT 25 COMMUNITY HOSPITALS AND CLINICS LAST YEAR. ALSO IN 2025, 13 SITES ENTERED THE START-UP PHASE IN THE HORIZON TWO CLINICAL TRIAL FOCUSED ON HIGH-RISK, NEWLY DIAGNOSED MYELOMA SO THEY COULD FULLY OPEN AND BEGIN SCREENING PATIENTS IN 2026. 2669588 0 0 DATA HELPS DRIVE EVERY BREAKTHROUGH IN MYELOMA. BY BUILDING AND SHARING LARGE, HIGH-QUALITY DATASETS, THE MMRF IS CREATING A LAUNCHPAD FOR THE NEXT WAVE OF TREATMENTS, IMPROVEMENTS IN CARE, AND, ULTIMATELY, CURES. IN 2025, THE MMRF LAUNCHED ITS NEXT INNOVATION IN DATA SHARING: THE MMRF VIRTUAL LABTM. VIRTUAL LAB IS NOW MYELOMA'S LARGEST, MOST-COMPREHENSIVE DATA-SHARING PLATFORM AND BRINGS ALL THE MMRF'S DATA INTO ONE PLACE. THE PLATFORM AND ITS ROBUST DATA WILL EMPOWER RESEARCHERS TO ASK BIGGER QUESTIONS, TEST NEW HYPOTHESES, AND ACCELERATE DISCOVERIES THAT IMPROVE OUTCOMES FOR PATIENTS WITH MYELOMA. 1600000 0 0 THE MAC PROGRAM PROVIDES $21 MILLION OVER 3 YEARS TO CREATE MULTICENTER TRANSLATIONAL RESEARCH TEAMS ACROSS GLOBAL MEDICAL CENTERS. EACH OF THESE THREE-YEAR MULTICENTER TRANSLATIONAL PROJECTS AIM TO FOSTER COLLABORATION AND ADVANCE COMPELLING HYPOTHESES THAT ARE READY FOR RAPID TESTING IN CLINICAL TRIALS, A CRITICAL STEP IN THE MMRF'S URGENT PURSUIT OF A CURE FOR EACH AND EVERY MYELOMA PATIENT. THE GRANTS ARE FOCUSED ON TWO CRITICAL AREAS OF UNMET NEED: OPTIMIZING FIRST-LINE THERAPY FOR NEWLY DIAGNOSED HIGH-RISK MYELOMA AND IMPROVING IDENTIFICATION OF HIGH-RISK SMOLDERING MYELOMA (HR SMM), AN EARLY, ASYMPTOMATIC STAGE THAT CAN PROCEED TO ACTIVE MYELOMA. IN 2025 THE COLLABORATING CENTERS CONTINUED TO MAKE POSITIVE PROGRESS, SHOWING THAT POOLING RESOURCES AND SAMPLES ACROSS A NETWORK OF INSTITUTIONS DRAMATICALLY IMPROVES THE ABILITY TO DRIVE MEANINGFUL RESULTS. 16987283 3576906 70864 BEYOND THE PROGRAM EXPENSES OUTLINED ABOVE, THE MMRF ALSO SUPPORTS A RANGE OF STRATEGIC INITIATIVES ALIGNED WITH ITS BROADER MISSION. THIS INCLUDES A ROBUST PORTFOLIO OF CUTTING-EDGE BASIC SCIENCE AND TRANSLATIONAL RESEARCH AIMED AT IDENTIFYING NEW THERAPEUTIC TARGETS THROUGH GENOMICS AND PROTEOMICS; VALIDATION STUDIES TO EXPLORE PROMISING COMPOUNDS AND TREATMENT COMBINATIONS; AND INNOVATIVE CLINICAL TRIALS FOCUSED ON NOVEL AND COMBINATION THERAPIES.FOUNDED BY PATIENTS, THE MMRF IS DEEPLY COMMITTED TO THOSE IMPACTED BY MYELOMA: PATIENTS, FAMILIES, PHYSICIANS, RESEARCHERS, AND INVESTORS. AT THE SAME TIME, THE MMRF DISTINGUISHES ITSELF THROUGH ITS BOLD AND COLLABORATIVE APPROACH. WE GENERATE, ANALYZE, AND SHARE THE LARGEST, MOST COMPREHENSIVE SET OF HIGH-QUALITY MYELOMA DATA, MAKING IT PUBLICLY AVAILABLE TO ACCELERATE PROGRESS. BY BRINGING TOGETHER THE RIGHT PEOPLE, PROGRAMS, AND TECHNOLOGIES, THE MMRF IS DRIVING THE RAPID DISCOVERY OF CURES FOR EACH AND EVERY PATIENT. 16987283 3576906 70864 27353091 1 1 0 0 0 0 0 0 0 0 1 0 1 0 1 1 0 1 0 0 1 1 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 1 49 0 80 1 0 0 0 0 0 0 0 0 0 0 0 0 X 14 14 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AR CA FL GA IL KS KY MD MA MI MN MS NH NJ NY NC OR PA RI SC TN VA WI WV X X X ALAN HEITNER 2036520207 383 MAIN AVENUE 7TH FLOOR NORWALK CT 06851 KATHY GIUSTI FOUNDER & DIRECTOR 2.00 X 0 0 0 THOMAS CONHEENEY CHAIRMAN 2.00 X X 0 0 0 GERALD MCDOUGALL VICE CHAIRMAN 2.00 X X 0 0 0 KENNETH ANDERSON MD DIRECTOR 2.00 X 0 0 0 KAREN ANDREWS DIRECTOR 2.00 X 0 0 0 RODNEY GILMORE DIRECTOR 2.00 X 0 0 0 DAVID LUCCHINO DIRECTOR 2.00 X 0 0 0 LORI TAUBER-MARCUS DIRECTOR 2.00 X 0 0 0 HUGH MARTIN DIRECTOR 2.00 X 0 0 0 WILLIAM MCKIERNAN DIRECTOR 2.00 X 0 0 0 DAVID PARKINSON MD DIRECTOR 2.00 X 0 0 0 MARIE PINIZZOTTO MD DIRECTOR THRU 12/31/2025 2.00 X 0 0 0 ADRIAN ROSENKRANZ DIRECTOR 2.00 X 0 0 0 STEVE SHAK MD DIRECTOR 2.00 X 0 0 0 KIMBERLY WHITE DIRECTOR 2.00 X 0 0 0 MICHAEL ANDREINI PRESIDENT & CEO 40.00 X 534635 0 33775 ALAN HEITNER TREASURER & CFO 40.00 X 230505 0 10706 KAREN DIETZ SECRETARY, CAO & GENERAL COUNSEL 40.00 X 287214 0 48042 ANNE QUINN YOUNG CHIEF MISSION OFFICER 40.00 X 374586 0 19455 GEORGE MULLIGAN CHIEF SCIENTIFIC OFFICER 40.00 X 370521 0 64920 HEARN CHO CHIEF MEDICAL OFFICER 32.00 X 227552 0 9080 STEPHANIE OESTREICH MANAGING DIRECTOR, MIF 40.00 X 397759 0 33610 KATIE WOZNIAK VP OF CLINICAL RESEARCH 40.00 X 244190 0 58555 PAM SPEER LEWIS VP OF DEVELOPMENT 40.00 X 224834 0 19800 GREG RUBENSTEIN VP OF MARKETING 40.00 X 220914 0 61822 JOANNE PUGLIA SR DIRECTOR FINANCE, CONTROLLER 40.00 X 199809 0 12143 ASHLEY BLANCHARD SR DIRECTOR, STRATEGIC PARTNERSHIPS 40.00 X 189544 0 57601 BRIAN HOCHBERG PRINCIPAL GIFT OFFICER 40.00 X 184995 0 55905 FRANCESCA LAROSA SR DIRECTOR, HUMAN RESOURCES 40.00 X 183151 0 26736 3870209 0 512150 41 0 1 0 ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI GUSTAVE L LEVY PLACE NEW YORK NY 10029 BIOTECHNOLOGY RESEARCH 3649842 ICON GOVERNMENT AND PUBLIC HEALTH SOLUTI 731 ARBOR WAY BLUE BELL PA 19422 BIOTECHNOLOGY RESEARCH 2668810 REDMEDED LLC 5 GREAT VALLEY PARKWAY SUITE 221 MALVERN PA 19355 CONTINUING MEDICAL EDUCATION 1393824 RELEVATE HEALTH GROUP LLC 8044 MONTGOMERY ROAD SUITE 700-738 CINCINNATI OH 45236 MARKETING CONSULTANT 950116 EVEREST CLINICAL RESEARCH CORPORATION 100 SOMERSET CORPORATE BOUELVARD BRIDGEWATER NJ 08807 BIOTECHNOLOGY RESEARCH 910373 34 26628081 625530 26628081 RESEARCH & CLINICAL TRIALS 541610 8674361 8674361 8674361 1162029 1162029 70864 70864 83535069 83547048 -11979 -11979 -11979 36523356 8745225 0 1150050 X 2171299 2171299 205607 205607 1200000 1200000 3189740 2701103 269860 218777 7259171 4597185 616724 2045262 253502 162762 20990 69750 934672 618576 82744 233352 694531 482213 59104 153214 592317 510934 8952 72431 122586 105743 1853 14990 63798 55032 964 7802 4125819 2401826 47616 1676377 1908430 1618048 28844 261538 1366541 874926 2991 488624 2015355 1738448 30460 246447 179428 154775 2712 21941 668993 465995 11855 191143 852187 474394 377793 573594 563232 2885 7477 164253 141685 2482 20086 CLINICAL TRIAL/RESEARCH 5903326 5903326 TISSUE BANKING 205982 205982 34651131 27353091 1191036 6107004 X 253696 126417 0 127279 2850860 3561044 6236082 9961812 4254361 4884191 1327848 6305891 487968 710293 2570033 1896574 2038895 673459 28979841 17683741 19702733 18734641 518560 357879 66397148 62872951 11501089 10559238 2407188 1374699 1974951 2575345 491527 335114 16374755 14844396 X 46293816 44811053 3728577 3217502 50022393 48028555 66397148 62872951 X 1872225 260157 -4126220 X X 0 1 X 1 0 X 37089868 42022114 30976388 24100727 26628081 160817178 37089868 42022114 30976388 24100727 26628081 160817178 15201828 145615350 100955 679638 1696550 1580287 1162029 5219459 6000 6000 166042637 17483456 0.87700 0.84980 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: OTHER INCOME - 2022 AMOUNT: $ 6,000. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 155342 47793 107549 2414691 1848781 565910 673459 ABCURO, INC. 1411251 F INDAPTA THERAPEUTICS 25000 F FORTIS THERAPEUTIC 500000 F CYTOIMMUNE THERAPEUTICS 1999995 F TRIUMVIRA IMMUNOLOGICS 1080222 F TELO THERAPEUTICS 1155884 F LUMINARY THERAPEUTICS 1000000 F KAHR MEDICAL LTD. 2666667 F NECTIN THERAPEUTICS 999995 F REVERB THERAPEUTICS 1499993 F OPNA BIO 1395634 F ENVISAGENICS 2000000 F NAMMI 500000 F TRIO 500000 F UMOJA 1000000 F STYLUS MEDICAINE 1000000 F 18734641 OPERATING LEASE LIABILITY 335114 335114 X 35557739 260157 694778 954935 34602804 1920552 1920552 36523356 32608298 694778 694778 31913520 2737611 2737611 34651131 PART X, LINE 2: THE MMRF RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. MANAGEMENT HAS DETERMINED THAT THE MMRF HAD NO UNCERTAIN TAX POSITIONS THAT WOULD REQUIRE FINANCIAL STATEMENT RECOGNITION OR DISCLOSURE. PART XI, LINE 4B - OTHER ADJUSTMENTS: SPECIAL EVENT EXPENSES RECLASSED TO PART IX 1,920,552. PART XII, LINE 4B - OTHER ADJUSTMENTS: SPECIAL EVENT EXPENSES RECLASSED TO PART IX 1,920,552. RETURN OF UNSPENT GRANT FUNDS 817,059. 1 NORTH AMERICA 0 0 GRANTMAKING 60000 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTMAKING 1110000 MIDDLE EAST AND NORTH AFRICA 0 0 INVESTMENTS 3666662 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 INVESTMENTS 1395634 NORTH AMERICA 0 0 INVESTMENTS 1499993 SUB-SAHARAN AFRICA 0 0 GRANTMAKING 30000 0 0 0 0 0 0 7762289 0 7762289 EUROPE (INCLUDING ICELAND & GREENLAND) MAC GRANT 1050000 WIRE 0 SUB-SAHARAN AFRICA FELLOWS 30000 WIRE 0 NORTH AMERICA FELLOWS 60000 WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) FELLOWS 60000 WIRE 0 4 0 1 0 1 0 0 0 PART I, LINE 2: MMRF RECEIVES PROGRESS REPORTS ON HOW THE GRANTED FUNDS ARE USED. MMRF CONDUCTS A REVIEW PROCESS, DURING WHICH THE INVESTIGATOR'S PROGRESS REPORT IS REVIEWED BY OUTSIDE REVIEWERS TO ENSURE THAT THE APPROPRIATE PROGRESS WAS MADE ON THE STUDY. ONCE THE RESEARCH EMPLOYEE ASSIGNED TO GRANT COORDINATION RECEIVES NOTIFICATION FROM THE REVIEWERS APPROPRIATE PROGRESS WAS MADE AND THE FINDINGS SUPPORT CONTINUES STUDY, HE/SHE PRESENTS THE PROGRESS AND FINDINGS TO AN APPROVAL COMMITTEE FOR A FUNDING RELEASE. SCHEDULE F, PART IV, LINE 1: THE ORGANIZATION IS REQUIRED TO FILE FORM 926 AS IT MEETS THE APPLICABLE FILING REQUIREMENT THRESHOLDS. SCHEDULE F, PART IV, LINE 3: THE ORGANIZATION IS NOT REQUIRED TO FILE FORM 5471 AS DOES NOT MEET THE APPLICABLE FILING REQUIREMENT THRESHOLDS OR OWNERSHIP AMOUNT. 1 BECKMAN RESEARCH INSTITUTE OF CITY OF HOPE 1450 EAST DUARTE ROAD DUARTE CA 91010 953432210 501(C)(3) 171210 0 SITE INVESTMENT GRANT BETH ISREAL DEACONESS MEDICAL CENTER 330 BROOKLINE AVENUE BOSTON MA 02215 042103881 501(C)(3) 136418 0 FELLOW, SITE INVESTMENT GRANT ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE PO BOX 1075 NEW YORK NY 10029 136171197 501(C)(3) 1150000 0 SITE INVESTMENT GRANT, MAC GRANT INDIANA UNIVERSITY 400 E 7TH STREET POPLARS 501 BLOOMINGTON IN 47405 356001673 501(C)(3) 60000 0 FELLOW TRUSTEES OF BOSTON UNIVERSITY 881 COMMONWEALTH AVE BOSTON MA 02215 042103547 501(C)(3) 35989 0 SCHOLARS UNIVERSITY OF MIAMI PO BOX 248106 CORAL GABLES FL 33124 590624458 501(C)(3) 30000 0 FELLOW UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 7007 BERTNER AVENUE SUITE 182457 HOUSTON TX 77030 760300816 501(C)(3) 426025 0 VLAB PROJECTS WASHINGTON UNIVERSITY IN ST LOUIS 660 EAST EUCLID AVENUE ST LOUIS MO 63110 430653611 501(C)(3) 157300 0 SITE INVESTMENT GRANT 8 0 FELLOWSHIP AWARDS 9 205607 PART I, LINE 2: GRANT MONITORING PROCEDURES THE MMRF MAINTAINS A FORMAL REVIEW, APPROVAL, AND MONITORING PROCESS FOR RESEARCH GRANTS AND CLINICAL/TRANSLATIONAL SITE SUPPORT AWARDS. RESEARCH BUDGET APPROVAL AND OVERSIGHT THE ANNUAL RESEARCH BUDGET IS INITIALLY REVIEWED AND APPROVED BY THE PROGRAMMING COMMITTEE. FOLLOWING PROGRAMMING COMMITTEE APPROVAL, THE BUDGET IS PRESENTED TO THE MMRF BOARD OF DIRECTORS FOR FINAL APPROVAL. RESEARCH AWARD ACTIVITY AND BUDGET PERFORMANCE ARE MONITORED ON AN ONGOING BASIS THROUGH MONTHLY RESEARCH PROGRAMMATIC MEETINGS WITH THE CEO AND CFO. THESE MEETINGS PROVIDE OVERSIGHT OF THE DISTRIBUTION AND MANAGEMENT OF RESEARCH AWARDS AND SERVE AS A FORUM TO REVIEW BUDGET UPDATES, CHANGES, AND REFORECASTS. ANY MATERIAL BUDGETARY CHANGE OR REFORECAST IN EXCESS OF $1 MILLION IS ESCALATED TO THE PROGRAMMING COMMITTEE FOR REVIEW AND DISCUSSION. THE MMRF AWARDS TWO PRIMARY TYPES OF GRANTS: CLASSICAL RESEARCH SUPPORT GRANTS AND CLINICAL/TRANSLATIONAL SITE SUPPORT GRANTS. CLASSICAL RESEARCH SUPPORT GRANTS CLASSICAL RESEARCH GRANT PROPOSALS ARE REVIEWED BY AN EXTERNAL GROUP OF SCIENTISTS WITH THE APPROPRIATE SUBJECT-MATTER EXPERTISE. SCIENTIFIC MERIT IS EVALUATED USING THE CURRENT NIH SCORING SYSTEM, WITH SCORES RANGING FROM 1 TO 9, WHERE 1 REPRESENTS THE HIGHEST SCIENTIFIC MERIT AND 9 REPRESENTS THE LOWEST. EACH PROPOSAL IS REVIEWED BY TWO INDEPENDENT EXTERNAL REVIEWERS, AND THE SCORES ARE AVERAGED. GRANTS SELECTED FOR FUNDING GENERALLY RECEIVE AN AVERAGE SCORE OF 3 OR BETTER. AFTER EXTERNAL SCIENTIFIC REVIEW IS COMPLETED, MMRF RESEARCH LEADERSHIP PERFORMS A FINAL REVIEW OF THE PROPOSALS AND MAKES FUNDING RECOMMENDATIONS TO THE CEO AND CFO FOR CONFIRMATION OF THE FINAL AWARDS. ONCE A GRANT AWARD IS APPROVED, AN AWARD LETTER IS ISSUED TO THE RECIPIENT, AND THE CFO IS NOTIFIED SO THAT THE APPROPRIATE GRANT ACCRUAL CAN BE RECORDED. GRANT PAYMENTS ARE SUBJECT TO CONTINUED MONITORING. AFTER THE INITIAL PAYMENT, THE INVESTIGATOR IS REQUIRED TO SUBMIT PROGRESS REPORTS IN ORDER TO RECEIVE SUBSEQUENT PAYMENTS. THESE PROGRESS REPORTS ARE REVIEWED BY EXTERNAL REVIEWERS TO DETERMINE WHETHER APPROPRIATE PROGRESS HAS BEEN MADE AND WHETHER THE FINDINGS SUPPORT CONTINUED FUNDING OF THE STUDY. ONCE THE RESEARCH EMPLOYEE RESPONSIBLE FOR GRANT COORDINATION RECEIVES CONFIRMATION THAT SUFFICIENT PROGRESS HAS BEEN MADE, THE PROGRESS AND FINDINGS ARE PRESENTED TO AN APPROVAL COMMITTEE FOR AUTHORIZATION OF THE NEXT FUNDING RELEASE. CLINICAL/TRANSLATIONAL SITE SUPPORT GRANTS CLINICAL AND TRANSLATIONAL SITE SUPPORT GRANT PROPOSALS ARE REVIEWED BY MMRF RESEARCH STAFF AND LEADERSHIP, IN COLLABORATION WITH OUTSIDE ADVISORS AS APPROPRIATE. MMRF RESEARCH LEADERSHIP THEN MAKES FUNDING RECOMMENDATIONS TO THE CEO FOR FINAL APPROVAL. ONCE A CLINICAL OR TRANSLATIONAL SITE SUPPORT GRANT IS APPROVED, AN AWARD LETTER IS ISSUED TO THE RECIPIENT, AND THE CFO IS NOTIFIED SO THAT THE APPROPRIATE GRANT ACCRUAL CAN BE RECORDED. THESE GRANTS ARE TYPICALLY RENEWED ANNUALLY OR STRUCTURED AS MULTI-YEAR AWARDS. CONTINUATION OR RENEWAL OF FUNDING IS BASED ON THE ACHIEVEMENT OF MILESTONES ESTABLISHED AT THE INCEPTION OF THE PROGRAM. THE MMRF ALSO MAINTAINS A CONFLICT-OF-INTEREST POLICY. ANY POTENTIAL CONFLICTS OR RELATED ISSUES ARISING IN CONNECTION WITH GRANT AWARDS ARE REVIEWED BY THE APPROPRIATE COMMITTEE. X X X X X 0 0 0 0 0 0 0 1 0 MICHAEL ANDREINI PRESIDENT & CEO 404078 0 130185 0 372 0 14000 0 19775 0 568410 0 0 0 GEORGE MULLIGAN CHIEF SCIENTIFIC OFFICER 281776 0 62620 0 26125 0 14000 0 50920 0 435441 0 0 0 STEPHANIE OESTREICH MANAGING DIRECTOR, MIF 322532 0 65400 0 9827 0 14000 0 19610 0 431369 0 0 0 ANNE QUINN YOUNG CHIEF MISSION OFFICER 279668 0 66198 0 28720 0 14000 0 5455 0 394041 0 0 0 KAREN DIETZ SECRETARY, CAO & GENERAL COUNSEL 208201 0 53416 0 25597 0 12140 0 35902 0 335256 0 0 0 KATIE WOZNIAK VP OF CLINICAL RESEARCH 207797 0 23903 0 12490 0 7725 0 50830 0 302745 0 0 0 GREG RUBENSTEIN VP OF MARKETING 181866 0 20910 0 18138 0 9702 0 52120 0 282736 0 0 0 ASHLEY BLANCHARD SR DIRECTOR, STRATEGIC PARTNERSHIPS 161179 0 14438 0 13927 0 8102 0 49499 0 247145 0 0 0 PAM SPEER LEWIS VP OF DEVELOPMENT 195905 0 15000 0 13929 0 0 0 19800 0 244634 0 0 0 ALAN HEITNER TREASURER & CFO 215412 0 0 0 15093 0 9200 0 1506 0 241211 0 0 0 BRIAN HOCHBERG PRINCIPAL GIFT OFFICER 162899 0 13500 0 8596 0 7902 0 48003 0 240900 0 0 0 HEARN CHO CHIEF MEDICAL OFFICER 170953 0 39952 0 16647 0 9080 0 0 0 236632 0 0 0 JOANNE PUGLIA SR DIRECTOR FINANCE, CONTROLLER 167694 0 13770 0 18345 0 8060 0 4083 0 211952 0 0 0 FRANCESCA LAROSA SR DIRECTOR, HUMAN RESOURCES 156365 0 12698 0 14088 0 7432 0 19304 0 209887 0 0 0 PART I, LINE 7 INDIVIDUALS INCLUDED IN SCHEDULE J, PART II RECEIVED A DISCRETIONARY BONUS DURING CALENDAR YEAR 2025, WHICH WAS INCLUDED IN COLUMN B(II) HEREIN AND IN THEIR 2025 FORM W-2, BOX 5, AS TAXABLE MEDICARE WAGES. X 34 625530 AVG. SELLING PRICE 0 0 1 0 PART I, COLUMN (B): THE ORGANIZATION IS REPORTING THE NUMBER OF CONTRIBUTORS. FORM 990, PART I, LINE 1: MMRF ACCOMPLISHMENTS FOR 2025 THE MULTIPLE MYELOMA RESEARCH FOUNDATION, INC. AND ITS WHOLLY OWNED SUBSIDIARIES, THE MULTIPLE MYELOMA RESEARCH CONSORTIUM, LLC ("MMRC") AND MYELOMA INVESTMENT FUND, LLC ("MIF"), COLLECTIVELY REFERRED TO AS "THE MMRF," IS THE LARGEST NONPROFIT IN THE WORLD SOLELY FOCUSED ON ACCELERATING A CURE FOR EACH AND EVERY MULTIPLE MYELOMA PATIENT. THE MMRF DRIVES THE DEVELOPMENT AND DELIVERY OF NEXT-GENERATION THERAPIES, LEVERAGES DATA TO IDENTIFY OPTIMAL AND MORE PERSONALIZED TREATMENT APPROACHES, AND EMPOWERS MYELOMA PATIENTS AND THE BROADER COMMUNITY WITH INFORMATION AND RESOURCES TO EXTEND THEIR LIVES. CENTRAL TO THE MMRF'S MISSION IS ITS COMMITMENT TO ADVANCING HEALTH EQUITY SO THAT ALL MYELOMA PATIENTS CAN BENEFIT FROM THE SCIENTIFIC AND CLINICAL ADVANCES THEY PURSUE. SINCE ITS INCORPORATION ON JANUARY 13, 1998, THE MMRF HAS COMMITTED OVER $600 MILLION FOR RESEARCH, SUPPORTED NEARLY 100 CLINICAL TRIALS AND RESEARCH STUDIES, AND HELPED BRING OVER 15 FDA-APPROVED THERAPIES TO MARKET, WHICH HAVE TRIPLED THE LIFE EXPECTANCY OF MYELOMA PATIENTS. IN 2025, THE MMRF INVESTED $27.1M IN CRITICAL RESEARCH PROGRAMS AND PATIENT EDUCATION PROGRAMS FOR MYELOMA PATIENTS. THROUGH THE MYELOMA INVESTMENT FUND (MIF), WE INVESTED IN TWO NEW EARLY STAGE BIOTECH COMPANIES PURSUING INNOVATIVE, POTENTIALLY GAME-CHANGING TREATMENTS FOR MYELOMA. THE HORIZON CLINICAL TRIALS PROGRAMRUN BY THE MULTIPLE MYELOMA RESEARCH CONSORTIUM (MMRC)MEANINGFULLY ADVANCED. THE HORIZON ONE TRIAL, FOCUSED ON RELAPSED/REFRACTORY MYELOMA, SURPASSED MANY OF ITS ENROLLMENT GOALS. HORIZON TWO BEGAN, FOCUSED ON HIGH-RISK, NEWLY DIAGNOSED PATIENTS, BEGAN ACTIVATING SITES AT THE END OF 2025. FORM 990, PART III, LINE 1: THE MULTIPLE MYELOMA RESEARCH FOUNDATION (MMRF) IS THE LARGEST NONPROFIT IN THE WORLD SOLELY FOCUSED ON ACCELERATING A CURE FOR EACH AND EVERY MULTIPLE MYELOMA PATIENT. WE DRIVE THE DEVELOPMENT AND DELIVERY OF NEXT-GENERATION THERAPIES, LEVERAGE DATA TO IDENTIFY OPTIMAL AND MORE PERSONALIZED TREATMENT APPROACHES, AND EMPOWER MYELOMA PATIENTS AND THE BROADER COMMUNITY WITH INFORMATION AND RESOURCES TO EXTEND THEIR LIVES. CENTRAL TO OUR MISSION IS OUR COMMITMENT TO ADVANCING HEALTH EQUITY SO THAT ALL MYELOMA PATIENTS CAN BENEFIT FROM THE SCIENTIFIC AND CLINICAL ADVANCES WE PURSUE. SINCE OUR INCEPTION, THE MMRF HAS COMMITTED OVER $600 MILLION FOR RESEARCH, SUPPORTED NEARLY 100 CLINICAL TRIALS AND RESEARCH STUDIES, AND HELPED BRING OVER 15 FDA-APPROVED THERAPIES TO MARKET, WHICH HAVE TRIPLED THE LIFE EXPECTANCY OF MYELOMA PATIENTS. FORM 990, PART VI, SECTION A, LINE 2 KATHY GIUSTI, FOUNDER & FORMER CHIEF MISSION OFFICER, AND KAREN ANDREWS, BOARD MEMBER HAVE A FAMILY RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS FIRST REVIEWED WITH THE CEO OF THE FOUNDATION. ONCE REVIEWED WITH THE CEO, THE FORM 990 IS EMAILED TO EACH BOARD MEMBER. EACH BOARD MEMBER REVIEWS THE FORM 990 AND IF ANY QUESTIONS ARISE, THEY ARE COMMUNICATED TO THE FOUNDATION AND ADDRESSED. AFTER ALL QUESTIONS ARE ADDRESSED, THE FORM 990 IS SUBMITTED TO THE IRS. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION'S CONFLICT OF INTEREST POLICY APPLIES TO ANY DIRECTOR, OFFICER, OR MEMBER OF A STANDING OR ADVISORY COMMITTEE WITH POWERS DELEGATED BY THE MMRF BOARD OF DIRECTORS WHO MAY HAVE A DIRECT OR INDIRECT FINANCIAL INTEREST (I.E. "INTERESTED PERSON"). DUTY TO DISCLOSE A POTENTIAL CONFLICT OF INTEREST: ANY INTERESTED PERSON MUST DISCLOSE THE EXISTENCE OF HIS OR HER FINANCIAL INTEREST TO THE BOARD OR AUDIT COMMITTEE AND MUST BE GIVEN THE OPPORTUNITY TO DISCLOSE ALL MATERIAL FACTS TO THE BOARD, MEMBERS OF THE AUDIT COMMITTEE AND ALL MEMBERS OF ANY COMMITTEE CONSIDERING THE PROPOSED CONTRACT OR TRANSACTION. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS: AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND ALL MATERIAL FACTS, AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, THE INTERESTED PERSON SHALL LEAVE THE BOARD OR AUDIT COMMITTEE MEETING WHILE THE DETERMINATION OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD OR AUDIT COMMITTEE MEMBERS, AS APPLICABLE, SHALL DECIDE IF A CONFLICT OF INTEREST EXISTS. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST: I. AN INTERESTED PERSON MAY MAKE A PRESENTATION AT THE BOARD OR AUDIT COMMITTEE MEETING, BUT AFTER SUCH PRESENTATION, HE OR SHE SHALL LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON, THE CONTRACT OR TRANSACTION THAT RESULT IN THE CONFLICT OF INTEREST. II. THE CHAIR OF THE BOARD OR CHAIRPERSON OF THE AUDIT COMMITTEE SHALL, IF APPROPRIATE, APPOINT A DISINTERESTED PERSON OR APPOINT OR ESTABLISH AN ADVISORY COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED CONTRACT OR TRANSACTION. AFTER EXERCISING DUE DILIGENCE, THE BOARD OR THE AUDIT COMMITTEE SHALL TAKE ALL REASONABLE STEPS TO DETERMINE WHETHER THE MMRF CAN OBTAIN A MORE ADVANTAGEOUS CONTRACT OR TRANSACTION WITH REASONABLE EFFORTS FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. IF A MORE ADVANTAGEOUS CONTRACT OR TRANSACTION IS NOT REASONABLY ATTAINABLE UNDER CIRCUMSTANCES THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST, THE BOARD OR AUDIT COMMITTEE SHALL DETERMINE BY A MAJORITY VOTE, BUT NOT LESS THAN TWO, OF THE DISINTERESTED DIRECTORS OR MEMBERS THEREOF WHETHER THE CONTRACT OR TRANSACTION IS IN THE MMRF'S BEST INTEREST AND IS FAIR AND REASONABLE TO THE MMRF; PROVIDED, HOWEVER, IF SUCH CONTRACT OR TRANSACTION IS APPROVED BY DISINTERESTED DIRECTORS WHO DO NOT SATISFY A QUORUM OR VOTING REQUIREMENT APPLICABLE TO THE AUTHORIZATION OF THE ACTION BY REASON OF THE MMRF'S CERTIFICATE OF INCORPORATION, BYLAWS OR A PROVISION OF LAW, THE ACTION MUST BE INDEPENDENTLY APPROVED BY SUCH INTERESTED AND DISINTERESTED DIRECTORS AS SATISFY THE APPLICABLE QUORUM OR VOTING REQUIREMENT. VIOLATION OF THE CONFLICTS OF INTEREST POLICY: III. IF THE BOARD OR AUDIT COMMITTEE HAS REASONABLE CAUSE TO BELIEVE THAT A DIRECTOR, OFFICER OR COMMITTEE MEMBER HAS FAILED TO DISCLOSE ACTUAL OR POSSIBLE CONFLICTS OF INTEREST, IT SHALL INFORM SUCH PERSON OF THE BASIS FOR SUCH BELIEF AND AFFORD SUCH PERSON AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. IF, AFTER HEARING THE RESPONSE OF THE DIRECTOR, OFFICER OR COMMITTEE MEMBER AND MAKING SUCH FURTHER INVESTIGATION AS MAY BE WARRANTED IN THE CIRCUMSTANCES, THE BOARD OR AUDIT COMMITTEE DETERMINES THAT SUCH PERSON HAS IN FACT FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, THE BOARD OR AUDIT COMMITTEE, AS APPLICABLE, SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION. FORM 990, PART VI, SECTION B, LINE 15 ALL SENIOR POSITIONS AND THEIR COMPENSATION ARE REVIEWED AND APPROVED BY THE BOARD OF DIRECTORS. COMPENSATION IS BENCHMARKED AGAINST OTHER 501(C)(3)'S, RESEARCH ORGANIZATIONS, THIRD PARTY COMPENSATION DATABASE AND THEN REVIEWED BY THE AUDIT AND FINANCE COMMITTEE. THE COMPENSATION APPROVAL IS DOCUMENTED IN THE MINUTES BY THE COMMITTEE. THIS PROCESS WAS LAST UNDERTAKEN IN 2025. FORM 990, PART VI, SECTION C, LINE 19 FINANCIAL STATEMENTS, GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, FORM 990 AND FORM 1023 ARE MADE AVAILABLE FOR PUBLIC VIEWING UPON WRITTEN REQUEST AT MMRF'S HEADQUARTERS. FORM 990 AND AUDITED FINANCIAL STATEMENTS ARE ALSO AVAILABLE AT THE ORGANIZATION'S WEBSITE: WWW.THEMMRF.ORG THE FORM 990 IS ALSO AVAILABLE ON WWW.GUIDESTAR.ORG, WWW.CHARITYNAVIGATOR.ORG, AND OTHER SIMILAR WEBSITES. FORM 990, PART IX, LINE 11G CONSULTING: PROGRAM SERVICE EXPENSES 1,053,065. MANAGEMENT AND GENERAL EXPENSES 25,938. FUNDRAISING EXPENSES 1,433,745. TOTAL EXPENSES 2,512,748. MEDICAL PROFESSIONALS: PROGRAM SERVICE EXPENSES 1,167,026. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 185,889. TOTAL EXPENSES 1,352,915. RECRUITING COSTS & TEMPORARY HELP: PROGRAM SERVICE EXPENSES 181,735. MANAGEMENT AND GENERAL EXPENSES 21,678. FUNDRAISING EXPENSES 56,743. TOTAL EXPENSES 260,156. FORM 990, PART XI, LINE 9: LOSS ON DISPOSAL OF ASSETS -1,590,337. IMPAIRMENT ON PROGRAMMATIC INVESTMENTS -3,352,942. RETURN OF UNSPENT GRANT FUNDS 817,059. FORM 990, PART XII, LINE 2C: THE MULTIPLE MYELOMA RESEARCH FOUNDATION, INC. AUDIT/FINANCE COMMITTEE RECOMMENDS THE AUDITOR TO THE BOARD, AND THE BOARD APPOINTS THE AUDITOR. THE BOARD ASSUMES RESPONSIBILITY FOR THE OVERSIGHT OF THE AUDIT OF ITS FINANCIAL STATEMENTS. THE POLICY FOR SELECTION AND OVERSIGHT OF THE INDEPENDENT AUDITORS HAS NOT CHANGED SINCE LAST YEAR. MYELOMA INVESTMENT FUND LLC 383 MAIN AVENUE 5TH FLOOR NORWALK CT 06851 471162865 VENTURE PHILANTHROPY FUND DE 5119292 20434115 THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC MULTIPLE MYELOMA RESEARCH CONSORTIUM LLC 383 MAIN AVENUE 5TH FLOOR NORWALK CT 06851 471142650 FACILITATING OR SPONSORING CLINICAL TRIALS AND RELATED RESEARCH CT 7955376 6932627 THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC